瑞士国家银行出售了糖尿病技术公司DexCom的股份,该公司仍面临高机构所有权和股价波动。
Swiss National Bank sold shares of diabetes tech firm DexCom, which still faces high institutional ownership and fluctuating stock prices.
瑞士国家银行在2020年第四季度通过出售48,400股股票减少了其在DexCom, Inc.的股权,现在拥有1,132,000股股票.
The Swiss National Bank reduced its stake in DexCom, Inc. by selling 48,400 shares in the fourth quarter of 2020, now owning 1,132,000 shares.
DexCom是一家医疗设备公司,侧重于糖尿病管理的连续葡萄糖监测系统,其机构所有权已增至其库存的97.75%。
DexCom, a medical device company focused on continuous glucose monitoring systems for diabetes management, has seen institutional ownership rise to 97.75% of its stock.
该公司的股票价格波动不定,一年一度最高,为142美元,最低,为62.34美元。
The company's stock price has fluctuated, with a one-year high of $142.00 and a low of $62.34.
DexCom的股票被评为“Moderate Buy”, 目标价格为99.82美元。
Despite missing analysts' earnings expectations, DexCom's stock is rated "Moderate Buy" with a target price of $99.82.